Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Tidal Investments LLC

Tidal Investments LLC grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 257.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,654 shares of the company's stock after acquiring an additional 2,633 shares during the period. Tidal Investments LLC's holdings in Medpace were worth $1,220,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. State Street Corp boosted its stake in Medpace by 7.2% during the 3rd quarter. State Street Corp now owns 752,957 shares of the company's stock valued at $251,337,000 after acquiring an additional 50,312 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Medpace by 7.6% during the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company's stock worth $209,885,000 after purchasing an additional 44,371 shares during the last quarter. Renaissance Technologies LLC grew its stake in Medpace by 38.3% in the second quarter. Renaissance Technologies LLC now owns 443,588 shares of the company's stock worth $182,692,000 after purchasing an additional 122,800 shares in the last quarter. Wellington Management Group LLP increased its holdings in Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock valued at $138,612,000 after buying an additional 109,886 shares during the last quarter. Finally, Clearbridge Investments LLC raised its stake in Medpace by 55.1% during the second quarter. Clearbridge Investments LLC now owns 403,892 shares of the company's stock valued at $166,343,000 after buying an additional 143,481 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Price Performance

Shares of MEDP traded up $4.15 during trading hours on Thursday, reaching $335.15. 289,959 shares of the company's stock traded hands, compared to its average volume of 282,603. Medpace Holdings, Inc. has a twelve month low of $277.72 and a twelve month high of $459.77. The business's fifty day simple moving average is $339.54 and its two-hundred day simple moving average is $366.89. The firm has a market capitalization of $10.42 billion, a price-to-earnings ratio of 29.35, a P/E/G ratio of 1.89 and a beta of 1.37.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating the consensus estimate of $2.77 by $0.24. The firm had revenue of $533.32 million for the quarter, compared to analysts' expectations of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. Medpace's quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the company earned $2.22 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on MEDP shares. Truist Financial decreased their target price on Medpace from $415.00 to $397.00 and set a "hold" rating for the company in a research report on Monday, October 14th. William Blair reaffirmed an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Jefferies Financial Group lowered shares of Medpace from a "buy" rating to a "hold" rating and decreased their price target for the company from $415.00 to $345.00 in a report on Wednesday, September 25th. StockNews.com lowered Medpace from a "buy" rating to a "hold" rating in a report on Friday, September 27th. Finally, Baird R W lowered Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Medpace currently has a consensus rating of "Hold" and a consensus target price of $380.56.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.